Capan-1 Cells

The Capan-1 cell line is derived from a human pancreatic adenocarcinoma and was established from the ascitic fluid of a 40-year-old Caucasian male. It was first characterized in 1975 and is particularly noted for its ductal epithelial morphology, which closely resembles that of primary pancreatic tumors. Capan-1 cells are extensively used in research aimed at understanding pancreatic cancer biology, including studies on tumor progression, metastasis, and treatment resistance. This cell line is well-regarded for its ability to produce mucin, a characteristic feature of many pancreatic adenocarcinomas, thus serving as a model for mucinous pancreatic cancer.

Genetically, Capan-1 harbors mutations in the KRAS gene, which are typical of pancreatic cancer, as well as alterations in other cancer-related genes such as TP53 and SMAD4. These mutations make the Capan-1 cell line a valuable tool for studying the molecular mechanisms underlying pancreatic cancer and for the preclinical evaluation of new therapeutic agents targeting these pathways. Furthermore, Capan-1 cells are used to study the biology of pancreatic cancer stem cells, offering insights into the behaviors that drive cancer recurrence and resistance to conventional therapies.